Multiple Myeloma in Relapse Clinical Trial
Official title:
Phase I Clinical Study of CAR-T Cells (C-4-29) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Verified date | April 2023 |
Source | Chongqing Precision Biotech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.
Status | Enrolling by invitation |
Enrollment | 18 |
Est. completion date | July 18, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. =18 years old, no gender limit; 2. Diagnosed with multiple myeloma according to the IMWG diagnostic criteria. 3. Received third-line and above regular treatments (including proteasome inhibitors or immunomodulators) that are ineffective or intolerable; 4. The disease is measurable during screening: 1. Serum M protein level =0.5g/dL, or urine M protein level =200mg/24h; 2. Or light chain type MM with undetectable serum or urine disease: serum immunoglobulin free light chain =10mg/dL and serum immunoglobulin ?/? free light chain ratio is abnormal; 3. Or evaluable extramedullary lesions with the largest transverse diameter = 1 cm. 5. ECOG 0~2 points; 6. The expected survival time is more than 12 weeks; 7. No serious mental disorders; 8. The function of important organs is basically normal: 1. Heart function: echocardiography indicates that the cardiac ejection fraction is =50%, and the electrocardiogram has no obvious abnormalities; 2. Renal function: serum creatinine=2.0×ULN; 3. Liver function: ALT and AST =3×ULN; 4. Total bilirubin and alkaline phosphatase=2×ULN (Gilbert syndrome=3.0×ULN); 5. Blood oxygen saturation>92%. 9. Have standards for apheresis or venous blood collection, and no other cell collection contraindications; 10. The subject agrees to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving C-4-29 cell infusion (excluding safe period contraception). 11. The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research. Exclusion Criteria: 1. Have received CAR-T therapy or other genetically modified cell therapy; 2. With central nervous system disease at the time of screening ; 3. Participated in other clinical studies within 1 month before screening; 4. Have received a live attenuated vaccine within 4 weeks before screening; 5. Have received the following anti-tumor treatments before apheresis: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); 6. Within 7 days before apheresis, there are active infections or uncontrollable infections that require systemic treatment (except CTCAE grade 1 genitourinary system infection and upper respiratory tract infection); 7. Suffered from plasma cell leukemia at the time of screening ; 8. Suffered from other malignant tumors other than multiple myeloma within 3 years before screening, except for the following cases: malignant tumors that have received radical treatment, and there is no known active disease for =3 years before enrollment; or fully treated non-melanoma skin cancer with no evidence of disease; 9. Except for hair loss or peripheral neuropathy, the toxicity of previous anti-tumor treatments has not improved to the baseline level or =grade 1; 10. Subjects who have received systemic steroid treatment within 7 days before apheresis or who have been determined by the investigator to require long-term systemic steroid treatment during treatment (except for inhaled or topical use); 11. Suffered from any of the following heart diseases: 1. NYHA stage III or IV congestive heart failure; 2. Myocardial infarction or CABG occurred =6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy. 12. Active autoimmune diseases; 13. HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive; 14. Have experienced a venous embolism event (for example: pulmonary embolism or deep vein thrombosis) and requires anticoagulation therapy or the subject meets the following conditions: a. Bleeding of grade 3 to 4 lasting more than 30 days; b. Have sequelae caused by venous thrombosis (such as persistent dyspnea and hypoxia); 15. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving C-4-29 cell reinfusion; 16. Other situations considered by the researcher to be unsuitable to participate in the study. |
Country | Name | City | State |
---|---|---|---|
China | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Chongqing Precision Biotech Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Overall survival after C-4-29 infusion | OS is defined as the time from C-4-29 cell infusion to death due to any cause | 2 years | |
Other | Progression-free survival after C-4-29 infusion | PFS is defined as the time from the start of the C-4-29 infusion to the first disease progression or death from any cause | 2 years | |
Other | Duration of relief after C-4-29 infusion | DOR is defined as the time from reaching MR or better to disease progression or death from any cause | 2 years | |
Primary | Incidence of Adverse events after C-4-29 infusion [Safety and Tolerability] | Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) | 28 days | |
Primary | Obtain the maximum tolerated dose of C-4-29 cells[Safety and Tolerability] | Dose-limiting toxicity after cell infusion | 28 days | |
Secondary | Objective response rate after C-4-29 infusion [Effectiveness] | Objective response rate includes sCR, CR, VGPR, PR, MR | 3 months | |
Secondary | AUCS of C-4-29 cells [Cell dynamics] | AUCS is defined as the area under the curve in 28 days | 3 months | |
Secondary | CMAX of C-4-29 cells [Cell dynamics] | CMAX is defined as the highest concentration of C-4-29 cells expanded in peripheral blood | 3 months | |
Secondary | TMAX of C-4-29 cells [Cell dynamics] | TMAX is defined as the time to reach the highest concentration | 3 months | |
Secondary | Peripheral blood M protein contents after C-4-29 infusion [Cell dynamics] | Periodic detection of Peripheral blood M protein after cell infusion | 3 months | |
Secondary | Urine Bence-Jones protein contents after C-4-29 infusion [Cell dynamics] | Periodic detection of Urine Bence-Jones protein after cell infusion | 3 months | |
Secondary | Immunogenicity of C-4-29 cells | Anti-CAR antibody | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01435720 -
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04094961 -
Ixazomib + Pomalidomide + Dexamethasone In MM
|
Phase 1/Phase 2 | |
Recruiting |
NCT06068400 -
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma
|
N/A | |
Recruiting |
NCT03601624 -
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
|
Phase 2 | |
Recruiting |
NCT05020444 -
TriPRIL CAR T Cells in Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT03706547 -
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
|
Phase 1 | |
Active, not recruiting |
NCT02970747 -
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
|
||
Not yet recruiting |
NCT06411301 -
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
|
Phase 1 | |
Completed |
NCT01965353 -
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT05581875 -
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
|
Phase 1/Phase 2 | |
Terminated |
NCT03687125 -
Tinostamustine Conditioning and Autologous Stem Cell
|
Phase 1/Phase 2 | |
Recruiting |
NCT06282978 -
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
|
Phase 2 | |
Recruiting |
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 | |
Active, not recruiting |
NCT03030261 -
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04925193 -
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
Recruiting |
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 | |
Terminated |
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 | |
Completed |
NCT03136653 -
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
|
Phase 1/Phase 2 |